Breaking News

Glatt, Innopharma in Particle Characterization Pact

July 10, 2014

To offer Eyecon to support real-time in-line characterization

Glatt and Innopharma Labs have entered a partnership to provide customers with access to Eyecon in-line particle characterization. Eyecon supports formulation development, scale-up, tech transfer and process optimization, both in the batch process and the continuous process. 

Eyecon is a self-contained, portable image capture and analysis sensor that can be mounted to inspection ports of Glatt equipment for in-line, real-time, non-product contact monitoring of particle morphology. According to the companies it can reduce batch losses and cycle time, improve yields, and provide greater control of process end points during granulation, coating, spheronizing and continuous fluid bed drying.
 
Eyecon imaging analysis collects relevant data for recipe development in real-time, and is designed to gain maximum transparency in the production process for complete documentation.
 
"This partnership provides Glatt Customers with access to Innopharma Labs advanced Eyecon technology enabling real-time in-line particle characterization data and images that directly aid process control,” said Ian Jones, chief executive officer of Innopharma Labs.
 
Reinhold Sprich, Glatt sales director, said, "We are delighted to offer customers this new and innovative technology. It demonstrates Glatt’s continued commitment to providing our customers with best of breed solutions.”
  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO